Primary immunodeficiency, secondary immnunodeficiency D80
Conditions
Interventions
Group 1: Data from children with PID or SID who received HyQvia for at least 6 months are taken retrospectively from the patient files. Demographic and clinical data as well as detailed data on the us
Sponsors
GWT-TUD GmbH, Medizin
Eligibility
Sex/Gender
All
Age
No minimum to 17 Years
Inclusion criteria
Inclusion criteria: 1.Patient with PID or SID has been on HyQvia infusion for at least 6 months 2.Patients was <18 years at the date of the 2nd documented HyQvia infusion 3.Patients/parent/guardian provided written informed consent for documentation. Data on the first HyQvia infusion and on the most recent HyQvia infusion are documented.
Exclusion criteria
Exclusion criteria: none
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HyQvia usage by patient characteristics (age, diagnosis, medical history), IgG treatment initiation, administration, and tolerability | — |
Secondary
| Measure | Time frame |
|---|---|
| • Adverse drug reactions (ADR) related to the full infusion interval of the 2 HyQvia infusions that are being captured) • Utilization of health resources (training sessions, nurse visits at home) • Physician’s therapy assessment | — |
Countries
Germany
Contacts
Public ContactDavid Pittrow
GWT-TUD GmbH
Outcome results
None listed